Pavmed (PAVM) closed at $1.63 on November 13, 2026, up 21.7% from the previous close, on volume of 54,924 shares (30-day average 13,210).
Data as of November 13, 2026.
PAVmed Earnings Call Highlights Lucid and Device Progress
TipRanks (Sat, 14-Nov 11:12 PM ET)
PAVmed to post Q3 non-GAAP adjusted net loss of $1.2M
Seeking Alpha News (Fri, 13-Nov 9:24 AM ET)
PAVmed Reports Medicare Reimbursement for Lucid EsoGuard Tests
TipRanks (Fri, 13-Nov 8:29 AM ET)
PAVmed Non-GAAP EPS of -$0.19 beats by $0.47
Seeking Alpha News (Fri, 13-Nov 8:08 AM ET)
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
PRNewswire (Fri, 13-Nov 8:00 AM ET)
Here are the major earnings before the open Friday
Seeking Alpha News (Thu, 12-Nov 6:00 PM ET)
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
PRNewswire (Thu, 12-Nov 8:04 AM ET)
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
PRNewswire (Thu, 5-Nov 8:25 AM ET)
PRNewswire (Wed, 4-Nov 8:55 AM ET)
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard Study
PRNewswire (Tue, 3-Nov 8:15 AM ET)
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
Pavmed trades on the NASDAQ stock market under the symbol PAVM.
As of November 16, 2026, PAVM stock price climbed to $1.75 with 144,318 million shares trading.
PAVM has a beta of 1.43, meaning it tends to be more sensitive to market movements. PAVM has a correlation of 0.04 to the broad based SPY ETF.
PAVM has a market cap of $17.22 million. This is considered a Sub-Micro Cap stock.
Last quarter Pavmed reported $41,000 in Revenue and -$.19 earnings per share. This beat revenue expectation by $16,000 and exceeded earnings estimates by $.54.
In the last 3 years, PAVM traded as high as $146.25 and as low as $1.17.
The top ETF exchange traded funds that PAVM belongs to (by Net Assets): VXF, IWC.
PAVM has underperformed the market in the last year with a price return of -83.5% while the SPY ETF gained +11.8%. PAVM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -63.1% and -10.3%, respectively, while the SPY returned -4.2% and -1.6%, respectively.
PAVM support price is $1.45 and resistance is $1.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PAVM shares will trade within this expected range on the day.